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Background: Dystrophic Epidermolysis Bullosa (DEB) is a rare genodermatosis (7 cases per million) that causes
blisters and erosions with minor trauma in skin and mucosa, and other systemic complications. A recently updated
systematic review showed that the research evidence about DEB therapies is poor. As new trials in DEB are difficult
and expensive, it is important to prioritizise research that patients and clinicians consider more relevant.
Objectives: To describe and prioritize the most important uncertainties about DEB treatment shared by patients,
carers and health care professionals (HCPs) in order to promote research in those areas.
Methods: A DEB Priority Setting Partnership (PSP) was established, including patients, carers and HCPs. DBE
uncertainties were gathered from patients and clinicians, and prioritized in a transparent process, using the
methodology advocated by the James Lind Alliance.
Results: In the consultation stage, 323 uncertainties were submitted by 58 participants. Once the duplicated and
non-treatment uncertainties were removed, the remainder were reduced to a list of 24 most voted questions.
These 24 uncertainties were prioritized in a final workshop where a balanced number of patients, carers and HCPs
selected the top 10 therapy uncertainties. The final list includes interventions in wound care, itch and pain
management, treatment and prevention of syndactyly, cancer prevention and future promising therapies.
Conclusions: The final list of the top 10 treatment uncertainties on the management of DEB provides guidance for
researchers and funding bodies, to ensure that future research answers questions that are important to both
clinicians and patients. The method proposed by the James Lind Alliance is feasible for very rare disorders.
Keywords: Dystrophic Epidermolysis Bullosa, Treatment uncertainties, Therapy uncertainties, Priority Setting
Partnership, Patient participation, Research prioritizationBackground
Dystrophic Epidermolysis Bullosa (DEB) is a rare genetic
skin disease (7:1,000,000 live births) [1] that produces
extreme fragility of skin and mucosa and blistering after
friction [2-4], as well as other systemic complications
(such as malnutrition, growth delay, infection, heart and
renal disease or skin-cancer) [5-12]. The patients have to* Correspondence: pauladavilaseijo@gmail.com
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distribution, and reproduction in any mediumlive with constant pain, scarring sequelae and eventually
disfigurement, disability and often, early death [13-16].
A recently updated systematic review of therapies for
inherited forms of Epidermolysis Bullosa (EB) identified,
up-to December 2011, seven randomized clinical trials
(RCTs) evaluating seven different interventions for de-
creasing number of skin lesions [17,18]. None of the
studied medications showed a significant effect. Most of
the studies were poorly reported, and of small size,
highlighting the difficulties of recruiting patients forntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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clinical questions have an uncertain answer.
As DEB is a rare disease, multi-centre trials with inter-
national collaboration are likely to be needed to solve
therapeutic uncertainties. As the research budget is lim-
ited and the number of uncertainties (unanswered clin-
ical questions) is large, prioritizing the most important
ones requiring research in DEB is essential [19]. The
traditional way of setting the research agenda is usually
led by researchers, academia and pharmaceutical indus-
try, but these groups might not focus on the same areas
as patients, carers and health care professionals (HCPs)
[20]. This mismatch has been the focus of recent atten-
tion [21], and the James Lind Alliance, funded by the
UK National Institute for Health Research [22], has de-
veloped a method (Priority Setting Partnerships (PSP)
[23] to identify and prioritize for research the treatment
uncertainties which patients, carers and clinicians agree
are the most important. The method consists of several
steps, including joining representative participants, col-
lecting uncertainties from them, excluding those that
can be answered with available research, and ranking the
remaining ones, the real uncertainties. There are few ex-
amples of the use of this method in dermatology [24,25],
and to our knowledge this has not been applied to very
rare disorders, where prioritization might be especially
important.
Materials and methods
The aim of the DEB PSP was to identify treatment un-
certainties that are relevant for patients and clinicians
and to prioritize them in a transparent process that can
help steer future clinical research.
The five stages of the PSP (see Figure 1 for a summary
of the methodology used), took place between November
2011 and October 2012.
The DEB PSP adopted the methods promoted by
the James Lind Alliance adapted to meet the needs of
this PSP.
The Steering Group comprised eight people with ex-
perience in DEB including patients/carers, a representa-
tive from the Dystrophic Epidermolysis Bullosa Research
Association Spain (DEBRA Spain), health care pro-
fessionals (dermatologists and nurses) and researchers/
epidemiologist.
Stage 1: Initiation
The aim of this stage was to establish the DEB PSP
through identifying and implicating potential stake-
holders. We contacted potential partner organizations
and individuals using the Steering Group members’ net-
works and through the DEBRA Spain´s register of affil-
iates. We tried to ensure that all the following groups
were represented: patients affected with DEB, carers ofchildren with DEB, physicians involved in EB care, nur-
ses, psychologist and other professionals related with
treatment and care of people with DEB.
Organizations approached at this stage were: The Dys-
trophic Epidermolysis Bullosa Research Association of
Spain (DEBRA Spain) and the Spanish Academy of Der-
matology and Venereology (AEDV).
To identify experts on the disease we used information
from DEBRA, DEBRA associates, physicians working in
centers with expertise in DEB care reference, and con-
tacted all authors of papers included in Medline, with an
address in Spain, and reporting a minimum of three pa-
tients. We also asked all experts to identify other experts
and justify their selection. To identify patients and ca-
rers we included all members of DEBRA Spain with
DEB (as many of them were children, their parents
were contacted).
Stage 2: Consultation survey: collection of treatment
uncertainties
The aim of this stage was to collect treatment uncertain-
ties using the following question: “What question(s)
about DEB treatment would you like to be answered by
research?” An pre-piloted online survey using Survey-
Monkey was carried out to collect uncertainties from pa-
tients, carers and healthcare professionals [26]. The
survey and informative documents were revised by pa-
tients in order to guarantee readability and easy under-
standing. A paper copy sent after a phone call was used
with to some participants who had no access to an e-
mail account. Details of the project and an informed
consent were also provided as attached documents.
Each participant submitted a maximum of twenty treat-
ment uncertainties. We additionally obtained information
about the category of each participant (patient, carer,
physician, nurse or other).
Additional treatment uncertainties were identified from
existing evidence: the “Updated systematic review of ran-
domized controlled trials of treatments for inherited forms
of Epidermolysis Bullosa” [17,18], NHS Evidence [27],
DEBRA America web page (Section Understanding EB)
[28] and other country-based or consensus guidelines
[4,29-31].
As a step required by the JLA method, we also con-
tacted UK-DUETs (UK Database of Uncertainties about
the Effects of Treatments) to include previously regis-
tered uncertainties in DBE [32].
Stage 3: Collation of treatment uncertainties
The aim of this stage was to review the treatment uncer-
tainties that we collected in the previous stage. Firstly,
we removed any uncertainty not related with therapy,
comments or personal queries. Then, we tried to refine
the uncertainties into a standard PICO format (Patients,
Figure 1 Summary of the methodology used in the PSP. DEB PSP, Dystrophic Epidermolysis Bullosa; HCPs, heath care professionals; EB,
Epidermolysis Bullosa; DEBRA, the Dystrophic Epidermolysis Bullosa Research Association; UK-DUETs, (UK Database of Uncertainties about the
Effects of Treatment).
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Figure 2 Summary of the results of the DEB PSP.
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bined any similar uncertainties. For example the uncer-
tainty “What is the best treatment to control itch in
DEB patients?” includes different systemic and topical
drugs.
This stage was carried out by two researchers. The full
list of refined uncertainties was checked by all members
of the Steering Group to ensure that the meaning of the
questions had not been modified, both during collation
and after translation into English, for the next step.
Thereafter, the complete list of uncertainties was sent
to UK-DUETs, reviewed and accepted for inclusion in
the UK-DUETs database.
Stage 4: Ranking exercise
The aim of this stage was to rank the uncertainties col-
lected and collated in the previous stages in order to cre-
ate a “Top-Twenty uncertainties” that were the most
important for patients, carers and HCPs. We sent a link
to a new on-line survey (or a paper copy) to all the par-
ticipants, asking them to select a maximum of five main
uncertainties. The order of the uncertainties in the sur-
vey was randomized in order to avoid response bias.
The results of this ranking were analyzed and sorted
on a rank order by frequency of votes. An analysis by
participants was also made to ensure that patients,
carers and HCPs were equally represented in the final
uncertainties´ compilation.
Stage 5: Final prioritization workshop
The aim of this final stage was to identify the top 10
most relevant uncertainties for DEB, obtained by con-
sensus between patients, carers and HCPs through a
workshop using the nominal group technique advocated
by the JLA. The participants were selected from individ-
uals that had carried out previous stages of the DEB,
from partner organizations and the Steering Group. Care
was taken to ensure a balanced number of patients,
carers and HCPs.
The workshop was half-day event, held at the Spanish
Academy of Dermatology and Venereology offices in
Madrid on 19 October 2012.
Participants were divided into three discussion groups,
with five participants each, an even representation of the
different groups (patients, carers and HCPs) and super-
vised by one facilitator who did not participate in the
discussion but ensured that all individuals took part
equally into the debate. All participants signed a declar-
ation of absence of conflicts of interests.
Further details of the methods used during the DEB
PSP are listed in the James Lind Alliance guidebook
(http://www.jlaguidebook.org).
Given the rarity of the disease and some circumstantial
problems, two of the participants in the workshop hadto participate remotely, using videoconference (with
SkypeW) and with the support of a moderator.Ethics
This project was approved by the “Comité Ético de
Investigacion Clínica”, Consellería de Sanidade, Xunta
de Galicia, Spain (reference 2011/378).Statistical methods
Data from all stages were stored in Microsoft Excel 2008
and analyzed with Stata 12.1 software (StataCorp College
Station, TX, USA). The survey was elaborated using the
Survey Monkey on-line application [26].Results
Stage 1: Initiation
As organizations, we contacted DEBRA and the AEDV.
The group of professionals included 29 participants, in-
cluding dermatologists, surgeons, dentists, pediatricians,
nurses, psychologists and a social worker. We contacted
125 patients- carers (Figure 2).
Figure 3 Final prioritization workshop process. All the
participants, with the two remote participants using videoconference,
during the final discussion. On the table, paper cards with each one of
the top 10 uncertainties ranked from the most important to the least.
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Of the 154 surveys sent, 62 (40%) were returned. The
response rate for patients and carers was 33% (41/125;
23 patients and 18 carers). 59% of HCPs consulted
responded (17/29). 40% of responses (23/58) were from
patients, 31% (18/58) were from careers and the re-
maining 29% (17/58) were from HCPs.
323 questions about DEB were obtained. The non-
treatment questions (n=51) and invalid ones (n=4) were
excluded. Once the duplicates were removed we ob-
tained seventy-three (n=73) uncertainties. Additional un-
certainties (n=50) extracted from the literature were
added. The resulting 123 uncertainties were refined into
a list of 77 uncertainties, all accepted in UK-DUETS
[27], which were used in the next stage (Figure 2).
Stage 4: Ranking exercise
A new survey was sent to the same individuals as in
consultation stage (n=154). Forty-six people answered
the survey (30%). The number of votes for each uncer-
tainty ranged from 17 to 0.
28% (13/46) of the responders were patients, 33%
(15/46) were carers and 39% (18/46) were HCPs.
Patients and carers were also asked to report a subject-
ive degree of their disease severity in order to assure that
patients of different severities were represented. 11%
(3/11) described themselves as suffering from mild dis-
ease, 39% (11/28) had moderate disease, 39% (11/28)
had severe DED and 11% (3/28) had very severe disease.
The range of age between the patients was 21 to 54
(median age 35.8 years) and the age range of affected
represented by carers was 3 to 23 (median age 10.3
years).
At the end of this stage a list of 24 uncertainties was
obtained (instead of 20, due to the presence of ties).
Stage 5: Final prioritization workshop
The final workshop was attended by three patients (of
different ages and gender), two carers, six HCPs and a
representative of DEBRA Spain as well as three facilita-
tors (see acknowledgements).
Each group independently selected their top ten un-
certainties. Then the three lists were joined into an over-
all ranking that was examined by all participants. After a
new discussion process, a “top ten” list was established
by consensus (Figure 3). There was a high level of agree-
ment amongst participants for the initial proposals in
the three groups. 15 uncertainties (out of 24) got all the
votes in the first round. The final top 10 ordered DEB
therapy uncertainties are listed below:
1. Which wound care method obtains better
outcomes (improved healing, decrease pain,
improve quality of life, decrease smell, preventinfection) in patients with EB? Interventions include
types of dressings (polyethylene, polyester plus
petrolatum, hydrocolloid, collagen, hydrofiber,
hydrogel, silicone…), topical antibacterial treatment
(clorhexidine, bleach bath, vinegar bath, honey,
antibiotics, silver dressings) and frequency of cure
(daily or alternate days)?
2. What is the best treatment to control itch in DEB
patients (sedating antihistaminics, non-sedating
antihistaminics, topical menthol, topical
corticosteroids, moisturizers, doxepin, gabapentine,
cyclosporine, dronabinol, ondansetron)?
3. What is the best pain control strategy (analgesics,
sedative drugs, addition of NaCl into the water) to
decrease pain during wound care and bath in DEB
patients?
4. How much does management in reference centers
help patients with DEB (in terms of quality of life,
avoiding complications and disability, cost-
effectiveness)?
5. How effective is a "tumor early diagnosis protocol"
in patients with DEB to decrease mortality,
amputations and disability?
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surgery? Which is the best technique? How often
should it be performed?
7. Which is the most effective method in avoiding
or delaying syndactyly in patients with DEB?
Including different types of bandages, dressings,
gloves and splints, physiotherapy and
occupational therapy.
8. What role might tissue engineering have in treating
wounds in patients with DEB?
9. What role might stem cell therapy and bone
marrow transplantation play in treating DEB?
10. What role might growth hormone play in
decreasing growth delay and puberty delayed in
DEB patients?
Some uncertainties were merged into one final uncer-
tainty when there was a complete agreement between
the participants.
Discussion
Working with DEB patients and HCP during the PSP
has highlighted the large number of uncertainties about
the treatment that both groups have and share.
The final workshop showed what were the main re-
search needs shared by patients, carers and HCP. These
were, in decreasing order of importance:
1. Wound care. This was a fundamental issue for
patients, carers and HCPs and is the one with more
unanswered questions about it.
2. Itch. It is an important issue for all participants,
leading to important discomfort and decreased
quality of life.
3. Pain. Pain is a big problem for DEB patients. It
was felt by participants that part of it could be
solved by proper application of current
knowledge, and involvement of pain management
specialists in DEB care. However, it was also felt
that there are some questions about pain therapy
that were specific for the disease, such as
treatment of pain during baths or during cures,
that might require specific research. (For example,
some authors report decreased pain after adding
salt to the bath water).
4. Neoplasms, especially issues of early detection and
treating squamous cell carcinoma.
5. Syndactyly. There is a lack of knowledge about what
the best method in preventing or delaying
syndactyly is as well as in correcting syndactyly once
it is established.
6. New therapies. There was a shared thought about
the importance of investigating new therapies in
order to discover a cure for the disease and also findnew techniques such as genetic engineering that
could offer betters outcomes in the most common
signs and symptoms of DEB. However these were
rated lower than research on everyday problems.
It is also important to mention the perceived need
to demonstrate the usefulness of reference centers in
decreasing complications and increasing quality of life
in order to encourage health authorities to develop
these centers.
We are aware of that some of the questions prioritized
may be broad, representing areas of concern more than
specific questions. This will be less useful for planning
research on them but, because there are so many uncer-
tainties in each field, all participants agreed that they
preferred a final list of uncertainties that reflects their
most relevant concerns even at the expense of being less
specific. However we believe that these areas of concern
can be easily transformed into more specific ones for re-
search. For example, the question about the best therapy
to relieve itch in DEB patients could lead to many differ-
ent questions that should also be prioritized: such as “do
DEB patients who take doxepin experience less itch than
those who do not?” or “is gabapentine more effective
than dronabinol in treating the itch among DEB pa-
tients? or maybe “do DEB patients who use topical corti-
costeroids experiment less itch than those do not?
To date, twenty PSP have been conducted by the
James Lind Alliance, mainly about common disorders
[23-25]. To the best of our knowledge, the DEB PSP is
the first PSP conducted about a very rare disease. In this
kind of diseases, due to its infrequency and scarce in-
vestment in research it is particularly important to
prioritize uncertainties. The main difference between
this PSP and the previous conducted by the JLA may be
resumed in several points:
Firstly, the lower number of patients and stakeholders:
These make it more difficult to identify them, but they
are easier to contact.
There was also difficulty in defining and finding expert
clinicians. Unlike in common disorders, where most
doctors will be experienced, and it is easy to find ex-
perts, for rare disorders there are many doctors caring
for very few patients and is hard to define who the ex-
pert clinicians are. In DEB there is an added difficulty, as
they require many different experts, from psychologists
to surgeons. We defined experts as those clinicians car-
ing for more than 10 patients with the disorder. To find
them we localized doctors of main reference centers and
asked them to identify other experts, we asked patients
and patient association to identify missing experts. We
also did a Medline search looking for authors of papers
on DEB describing more than 3 patients in our country.
Using this combined strategy we think that we have
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sample is highly representative of them, as all identified
experts have participated in the PSP.
Finally, given the scarcity of participants it was difficult
to schedule a meeting with participants balanced in
terms of age, sex and severity that they could all attend.
Two of the participants could not be at the meeting, and
has to participate remotely, via teleconference (using
Skype®). For researchers planning other PSPs, it can be
interesting to notice that remote participation with the
help of a moderator was feasible (only one remote assist-
ant per group and both in the final global discussion),
and that those participants felt integrated in the discus-
sion process.
One of the weaknesses of this PSP might be the low
number of participants (patients, HCPs and organiza-
tions) compared to other PSPs, which might jeopardize
its generalizability. This would be true in absolute terms
but it is important to take into account that prevalence
of DEB is very low (7 cases per million) [33], the number
of associations is scant and there are no many HCPs ex-
perts in treating DEB patients. Due to this rarity it was
easy to approach most of the patients (because DEB is
such a devastating disease, most of the patients and
carers are members of DEBRA Spain) and experts in
Spain. This, added to a high response rate (40%) when
compared to other PSPs, makes the results very likely of
being representative of the treatment uncertainties among
patients and HCPs.
This PSP has been conducted in Spain, with some help
from James Lind Alliance and following their methods.
We do not think that the uncertainties found or the pri-
orities are country specific, and thus they can be gener-
alized to most settings. However, international aspects of
the prioritization process advocated by the James Lind
Alliance are worth further study, both in terms of im-
proving methods to make international collaboration
easier and to study whether results are reproducible and
can be generalized to other countries.
Conclusions
The final aim of this PSP was to uncover the uncertain-
ties about DEB, and to prioritize them to fit the per-
ceived needs of patients, carers and HCPs in this rare,
but devastating, disease. We hope that the prioritized
uncertainties are useful for researchers and funding bod-
ies. PSP can be done in rare disorders, and are more im-
portant in these disorders as the budget for research is
more limited.
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